Patents Examined by Stacy Brown
-
Patent number: 10172929Abstract: The invention provides flavivirus vaccines and methods of making and using these vaccines.Type: GrantFiled: October 6, 2014Date of Patent: January 8, 2019Assignee: Sanofi Pasteur Biologics, LLCInventors: Thomas P. Monath, Farshad Guirakhoo, Juan Arroyo, Konstantin V. Pugachev
-
Patent number: 10092637Abstract: Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.Type: GrantFiled: September 12, 2016Date of Patent: October 9, 2018Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Gwong-Jen J. Chang, Wayne D. Crill, Holly R. Hughes, Brent S. Davis
-
Patent number: 10081669Abstract: The present invention addresses a need for improved treatments for Filovirus infections.Type: GrantFiled: May 23, 2016Date of Patent: September 25, 2018Assignees: Albert Einstein College of Medicine, Inc., The Governing Council of the University of Toronto, The United States of America as Represented by the Secretary of the ArmyInventors: Jonathan R. Lai, Jayne F. Koelhoffer, Julia Frei, Kartik Chandran, Sachdev Sidhu, Gang Chen, John M. Dye, Jr., Samantha Zak
-
Patent number: 10080794Abstract: Disclosed are compositions and methods comprising vectors and a reverse genetics competent unit comprising one or more recombinant influenza viruses. Recombinant influenza viruses comprising swine RNA polymerase I promoter are disclosed. Constructs comprising swine RNA polymerase I promoter nucleic acid sequences are also provided. Methods of inducing protecting immunity with the recombinant influenza viruses are disclosed. In certain embodiments, the reverse genetics competent unit comprises pathogenic units necessary for producing pathogens de novo from a nucleotide-based vector for influenza virus in swine.Type: GrantFiled: March 15, 2014Date of Patent: September 25, 2018Assignee: UNIVERSITY OF MARYLAND, COLLEGE PARKInventors: Daniel R. Perez, Matthew Angel
-
Patent number: 10080793Abstract: The present invention relates to a method for prevention and/or reduction of aggregation of viral components.Type: GrantFiled: June 17, 2014Date of Patent: September 25, 2018Assignee: De Staat der Nederlanden, vert, door de minister van VWS, Ministerie van Volksgezonheid, Welzijn en SportInventors: Arend Gesinus van't Oever, Wilfridus Adrianus Maria Bakker, Yvonne Elisabeth Thomassen
-
Patent number: 10053672Abstract: The present invention relates to a method for obtaining an untransformed avian cell line enabling in vitro avian virus replication. Said method includes the following steps: a) culturing avian embryonic stem cells in the presence of a stroma for at least 3 days; b) culturing for at least 2 days in a medium having a low serum concentration; c) culturing for at least 2 days in a medium having a low serum concentration containing 1 to 10 mM of hexamethyleme bisacetamide (HMBA); d) culturing for at least 10 days in a medium having a low serum concentration; and e) culturing or freezing an avian cell line enabling avian virus replication. The invention also relates to the resulting cell line and to the use thereof in vaccine preparations.Type: GrantFiled: July 24, 2014Date of Patent: August 21, 2018Assignee: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUEInventors: Jean-François Vautherot, Bertrand Pain, Caroline Denesvre, Laetitia Fragnet-Trapp
-
Patent number: 10010600Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4.Type: GrantFiled: November 6, 2015Date of Patent: July 3, 2018Assignee: TAKEDA VACCINES, INC.Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
-
Patent number: 9989530Abstract: The present invention provides monoclonal antibodies that are specific for the Dengue non-structural glycoprotein NS1 in monomeric and/or oligomeric (primarily dimeric) form, together with methods, including ELISA and lateral flow assays, that employ the disclosed antibodies for the early detection of Dengue virus infection. Diagnostic kits for the detection of Dengue infection are also provided, such kits including the disclosed monoclonal and/or polyclonal antibodies.Type: GrantFiled: November 22, 2016Date of Patent: June 5, 2018Assignee: InBios International, Inc.Inventors: Syamal Raychaudhuri, Raymond L. Houghton, Stanislaw Morkowski, Yvonne Stevens, Mohua Bose, James William Needham, Hongjing Chen
-
Patent number: 6855493Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: November 28, 2001Date of Patent: February 15, 2005Assignee: MedImmune, Inc.Inventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins
-
Patent number: 6630144Abstract: In this application are described Ebola GP monoclonal antibodies and epitopes recognized by these monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of Ebola virus infections in vitro and in vivo.Type: GrantFiled: August 29, 2000Date of Patent: October 7, 2003Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Mary K. Hart, Julie A. Wilson, Alan L. Schmaljohn
-
Patent number: 6627617Abstract: The present invention provides temperature-sensitive (ts) adeno-associated virus (AAV) Rep78 and Rep68 proteins. In preferred embodiments, the ts AAV Rep78 and Rep68 proteins have missense mutations at amino acid positions 40, 42 and 44 that confer a temperature-sensitive phenotype. Also provided are nucleotide sequences and vectors encoding the inventive ts Rep proteins. In preferred embodiments, a hybrid adenovirus vector is provided that stably comprises a nucleotide sequence encoding a ts AAV Rep protein according to the invention. The present invention also provides methods of packaging AAV vectors and methods of ex vivo gene delivery using the ts Rep proteins of the invention. Further provided are cells containing the ts AAV Rep proteins, preferably stably integrated into the genome of the cell.Type: GrantFiled: September 29, 2000Date of Patent: September 30, 2003Assignee: University of North Carolina at Chapel HillInventors: Richard Jude Samulski, Denise Gavin, Nicholas Muzyczka, Corinne Abernathy, Daniel Pereira
-
Patent number: 6613507Abstract: Methods for treating patients with viral infections and Parkinson's disease with pharmaceutical agents are disclosed. In one embodiment, the viruses are Hepatitis C, Influenza A and B. The Pharmaceutical agents are 1-boraadamantane and the conjugate amines described in this patent application.Type: GrantFiled: March 21, 2001Date of Patent: September 2, 2003Inventor: Yu-An Chang
-
Patent number: 6521426Abstract: Adenoviral particles are produced by incubating cells containing a helper adenovirus vector and a helper-dependent adenoviral vector including an Adeno-Associated Virus (AAV) rep gene, such as rep 78. Cells are provided containing a helper adenovirus vector. A helper-dependent adenoviral vector including an AAV rep gene is introduced into the cells, for instance by infection with infective viral particles. The cells are incubated to produce adenoviral particles containing nucleic acid including the AAV rep gene. Advantageously, cells containing helper adenovirus vector are pre-incubated for 0.5-12 hours, preferably about 4 hours, to allow expression of viral proteins required for adenoviral genome replication before introducing the helper-dependent adenovirus vector including an AAV rep gene.Type: GrantFiled: December 8, 2000Date of Patent: February 18, 2003Assignee: Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.Inventors: Gennaro Ciliberto, Stefano Colloca, Nicola La Monica
-
Patent number: 6471964Abstract: The present invention concerns a nucleic acid encoding a structural protein of Infectious Salmon Anaemia Virus (ISAV) designated as Structural Protein-1 (SP-1), the isolated SP-1 protein, and use of the nucleic acid and/or protein for diagnostic or vaccine purposes. The invention furthermore pertains to antibodies that are reactive with said SP-1 and their use in diagnostics.Type: GrantFiled: October 17, 2000Date of Patent: October 29, 2002Assignee: Akzo Nobel N.V.Inventors: Eirik Biering, Bjørn Krossøy
-
Patent number: 6464976Abstract: The present invention provides an apparatus and method to diminish the pre-existing immune response to the administration of a therapeutic virus by the selective elimination of antiviral antibodies from the serum. The present invention provides a chromatographic material for the elimination of such antibodies. The invention further provides plasmapheresis apparatus comprising this material. The invention further provides methods for the employment of such apparatus as part of therapeutic treatment regiments.Type: GrantFiled: August 31, 2000Date of Patent: October 15, 2002Assignee: Canji, Inc.Inventors: Drake M. LaFace, Amena Rahman, Paul W. Shabram, Van T. Tsai
-
Patent number: 6458370Abstract: Compositions are provided which include biodegradable microparticles with entrapped or adsorbed antigens, in combination with submicron oil-in-water emulsions. Also provided are methods of immunization which comprise administering to a vertebrate subject (a) a submicron oil-in-water emulsion, and (b) a therapeutically effective amount of a selected antigen entrapped in a microparticle.Type: GrantFiled: August 20, 2001Date of Patent: October 1, 2002Assignee: Chiron CorporationInventors: Derek O'Hagan, Gary Van Nest, Gary S. Ott, Manmohan Singh
-
Patent number: 6432926Abstract: By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2ad/db protein, either directly or by gene transfer techniques, to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.Type: GrantFiled: July 27, 1999Date of Patent: August 13, 2002Assignee: President and Fellows of Harvard CollegeInventors: Peter M. Howley, Jennifer J. Dowhanick-Morrissette, John D. Benson, Hiroyuki Sakai